Your session is about to expire
← Back to Search
Multimodal Pharmacological Management for Pain
Study Summary
This trial will compare two local anesthetic blocks in different locations for postoperative pain control after lumbar spinal fusion, to see if it reduces opioid use.
- Pain
- Opioid Use Disorder
- Slipped Disc
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Is this clinical trial only available to patients who are under 30 years old?
"In order to be included in this particular trial, patients must be between 40 and 80 years old. Out of the 838 total clinical trials, this is one of the 133 that focuses on a younger demographic and one of the 705 that focuses on an older demographic."
Are we still welcoming people who want to participate in this research?
"That is correct, the listing on clinicaltrials.gov does show that the research team is actively looking for participants. The trial was first advertised on December first 2020 and was most recently updated on March 18th 2021. They are currently trying to enrol 30 individuals at a single site."
What does Multimodal Pharmacological Management usually address?
"Multimodal Pharmacological Management is a standard course of treatment for cervical syndrome. It is also effective in treating conditions such as minor burns, labour, and transplantation."
Are there other examples where doctors have used multiple drugs to manage a condition?
"202 ongoing studies for Multimodal Pharmacological Management exist as of now, with 49 in Phase 3. Most clinical trials for this topic are situated in Duarte, CA, but there are 1196 locations running similar trials."
Has the FDA acknowledged the benefits of Multimodal Pharmacological Management?
"The safety of Multimodal Pharmacological Management has been well-documented in Phase 3 trials, leading our team to rate it a 3 on our safety scale."
Share this study with friends
Copy Link
Messenger